menu search

Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-dependent anemia and […] The post Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of... Read More
Posted: Jun 14 2023, 13:49
Author Name: forextv
Views: 081248

Search within

Pages Search Results: